Aurinia Pharmaceuticals
7298 Upper Clarenton Drive South
New Albany
OH
43054
United States
86 articles with Aurinia Pharmaceuticals
-
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
5/20/2022
Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals.
-
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
5/16/2022
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 59th European Renal Association (ERA) Congress and at the European Congress of Rheumatology, European Alliance of Associations for Rheumatology (EULAR) 2022.
-
Aurinia Reports First Quarter 2022 Financial and Operational Results
5/10/2022
Aurinia Pharmaceuticals Inc. issued its financial results for the first quarter ended March 31, 2022.
-
In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.
-
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
5/6/2022
Aurinia Pharmaceuticals Inc. announces a change to the dial-in number for the upcoming first quarter financial and operational results announcement on Tuesday, May 10, 2022.
-
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022
5/2/2022
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022, before markets open.
-
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
4/19/2022
Aurinia Pharmaceuticals Inc. today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs.
-
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
4/4/2022
Aurinia Pharmaceuticals Inc. today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 2022 National Kidney Foundation Spring Clinical Meetings, taking place April 6-10, 2022 in Boston, Mass.
-
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences in March 2022
3/3/2022
Aurinia Pharmaceuticals Inc. announced that members of the executive management team will give corporate presentations at two upcoming investor conferences including.
-
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
2/28/2022
Aurinia Pharmaceuticals Inc. issued its financial results for the fourth quarter and year ended December 31, 2021.
-
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021
2/9/2022
Aurinia Pharmaceuticals Inc. announced that it will release its fourth quarter and year end 2021 financial results on Monday, February 28, 2021, before markets open.
-
Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference
2/3/2022
Aurinia Pharmaceuticals Inc. announced that the company will deliver a corporate presentation at the 11th Annual Leerink Global Healthcare Conference.
-
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
1/4/2022
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences.
-
On December 28, the U.S. Food and Drug Administration reported there had been 50 novel drug approvals for the year, and that was just for new chemical entities.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
12/9/2021
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™.
-
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
11/10/2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November 16-19, 2021.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Bristol Myers Squibb’s Phase III CheckMate -816 trial hit the primary endpoint in an interim analysis.
-
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
11/3/2021
Aurinia Pharmaceuticals Inc. issued its financial results for the third quarter ended September 30, 2021.